Labtec opens GMP-compliant manufacturing plant in Europe for transdermal patches and oral filmsLabtec opens GMP-compliant manufacturing plant in Europe for transdermal patches and oral films
March 11, 2015
After 1.5 years and considerable investment by its parent company, tesa SE, Labtec GmbH has become a fully authorized manufacturer for transdermal drug delivery systems (TDS) and oral dispersible films (ODF) with its proprietary RapidFilm technology.
The facility is located within tesa's largest manufacturing site, tesa Werk Hamburg GmbH, south of the city of Hamburg, Germany. The production facility provides for industrial mass production and includes state-of-the-art coating and drying lines with variable coating widths as well as modern slitting machinery and high-precision, flexible converting and packaging equipment dedicated to TDS and ODF. The plant operates with a cleanroom environment, is fully GMP compliant and offers sufficient space for future expansion.
Following a three-day inspection in March 2011, the Hamburg health authorities certified the facility as GMP compliant. With completion of this final step in setting up production capability for transdermal therapeutic systems and oral dispersible films, Labtec GmbH now offers full-fledged contract manufacturing of TDS and ODF finished products in addition to its traditional contract development services.
Ingo Lehrke, managing director at Labtec is very satisfied: "It took only one and a half years from the initial planning phase until completion of construction and start of operation of the unit. This quick implementation is the result of an extremely close and dedicated cooperation between experts from tesa, Beiersdorf and Labtec. We are now able to combine Labtec's pharmaceutical know-how with tesa's extensive manufacturing expertise to supply our customers with innovative drug delivery products."
Source: Labtec GmbH
About the Author(s)
You May Also Like